Triumvira Immunologics, Inc. logo

Triumvira Immunologics, Inc.

Triumvira Immunologics Inc. is a biotechnology company developing a novel platform - T Cell-Antigen Coupler (TAC), by engineering T cells to attack cancers.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://triumvira.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
175 Longwood Road South Suite 305, ON, L8P 0A1
Hamilton
Canada
Email
Contact Number
+1 289-799-6463

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/triumvira-immunologics” connections=”true” suffix=””]

The TAC platform represents a novel and innovative approach to engineered T cells. Unlike the Chimeric Antigen Receptors, TACs activate T cells through the T cell receptor, redirecting it towards cell surface antigens. This approach may yield a more regulated activation and proliferation of T cells in response to antigen binding, potentially yielding clinical benefits.

In Nov 2015, Triumvira raised $1.8 Mn in seed financing round. The proceeds of the funding is used to retain management and to support sponsored research of the companys T CellAntigen Coupler (TAC) platform at McMaster University.